← Back to Clinical Trials
Recruiting NCT06500494

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment

Trial Parameters

Condition Advanced Breast Cancer
Sponsor Pierre Fabre Medicament
Study Type OBSERVATIONAL
Phase N/A
Enrollment 368
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2024-09-10
Completion 2028-02
Interventions
Vinorelbine Tartrate Oral

Brief Summary

This study looks at how well oral vinorelbine works in treating advanced breast cancer. It looks at women who have already had this treatment or are currently having it.

Eligibility Criteria

Inclusion Criteria: Female aged ≥ 18 years (≥ 19 years for Algeria as per local regulation) at oral vinorelbine ( OV) -based treatment initiation Confirmed diagnosis of locally advanced or metastatic breast cancer eligible for chemotherapy Initiated OV-based treatment as per SmPC for advanced breast cancer between January 2011 and December 2020 for the retrospective cohort or, initiating oral vinorelbine treatment at enrollment for the prospective cohort Willing and able to complete the QoL questionnaire, PPQ and WPAI questionnaire for the prospective cohort Provision of informed consent or non-opposition to the patient (or next of kin/legal representative, if applicable) for the use of data, according to local regulations Exclusion Criteria: no exclusion criteria for patients in this study

Related Trials